A | B |
---|---|
Disease | |
Brucellosis | • Arthritis. |
• Cardiovascular, nervous, and respiratory system infections. | |
• Chronic meningitis and meningoencephalitis. | |
• Deafness. | |
• Demyelinating meningovascular syndromes. | |
• Episcleritis. | |
• Fatigue, inattention, amnesia, and depression. | |
• Guillain-Barré syndrome. | |
• Hepatic abnormalities, including granulomatous hepatitis. | |
• Multifocal choroiditis. | |
• Myelitis-radiculoneuritis. | |
• Nummular keratitis. | |
• Papilledema. | |
• Optic neuritis. | |
• Orchioepididymitis and infections of the genitourinary system. | |
• Sensorineural hearing loss. | |
• Spondylitis. | |
• Uveitis. | |
Campylobacter jejuni | • Guillain-Barré syndrome if manifest within 2 months of the infection. |
• Reactive Arthritis if manifest within 3 months of the infection. | |
• Uveitis if manifest within 1 month of the infection. | |
Coxiella burnetii (Q fever) | • Chronic hepatitis. |
• Endocarditis. | |
• Osteomyelitis. | |
• Post-Q-fever chronic fatigue syndrome. | |
• Vascular infection. | |
Malaria | • Demyelinating polyneuropathy. |
• Guillain-Barré syndrome. | |
• Hematologic manifestations (particularly anemia after falciparum malaria and splenic rupture after vivax malaria). | |
• Immune-complex glomerulonephritis. | |
• Neurologic disease, neuropsychiatric disease, or both. | |
• Ophthalmologic manifestations, particularly retinal hemorrhage and scarring. | |
• Plasmodium falciparum. | |
• Plasmodium malariae. | |
• Plasmodium ovale. | |
• Plasmodium vivax. | |
• Renal disease, especially nephrotic syndrome. | |
Mycobacterium tuberculosis | • Active tuberculosis. |
• Long-term adverse health outcomes due to irreversible tissue damage from severe forms of pulmonary and extrapulmonary tuberculosis and active tuberculosis. | |
Nontyphoid Salmonella | • Reactive Arthritis if manifest within 3 months of the infection. |
Shigella | • Hemolytic-uremic syndrome if manifest within 1 month of the infection. |
• Reactive Arthritis if manifest within 3 months of the infection. | |
Visceral leishmaniasis | • Delayed presentation of the acute clinical syndrome. |
Code of Federal Regulations
252
|
|
• Post-kala-azar dermal leishmaniasis if manifest within 2 years of the infection. | |
• Reactivation of visceral leishmaniasis in the context of future immunosuppression. | |
West Nile virus | • Variable physical, functional, or cognitive disability. |